Elektrofi · 6 hours ago
Executive Director, Business Development
Boston, MA
Full-time
Onsite
Director/Executive
$245K/yr - $299K/yr
18+ years expHalozyme Hypercon, a subsidiary of Halozyme Therapeutics, Inc., is dedicated to transforming drug delivery and enhancing patient experiences. The Executive Director, Business Development - Hypercon will lead business development efforts, focusing on identifying and negotiating new partnerships to advance the Hypercon platform and drive growth.
Alternative MedicineBiotechnologyTherapeutics
Responsibilities
Contribute toward the development of the Hypercon Business Development strategies to grow the drug delivery business
Identify potential new Hypercon collaborations through self and team directed opportunity analyses, business meetings and reading of new publications and data
Develop and demonstrate a strong technical knowledge of the Hypercon platform and technical development pathways
Develop and implement plans to engage key stakeholders and decision-makers within the companies where potential opportunities exist, winning opportunities with communication of well thought through and compelling value propositions, supported by technical and commercial analyses
CDA and MTA agreement negotiation efforts required to progress deal flow
Advance deal negotiations including development of draft Collaboration and Licensing Agreements including gaining internal alignment on proposed terms based on opportunity assessment, leading the negotiation, including tracking and resolving issues through discussion with internal stakeholders, and building agreement with external counterparts
Develop deep knowledge of market landscapes and trends, major product developments, trial outcomes, and company activity in the relevant areas of interest
Regularly update and strengthen the Hypercon non-confidential and confidential partnering materials and be proficient in presenting this material to prospective partners and responding to questions
Perform financial and market modeling in Microsoft Excel, creating presentation slides to support strategy and business development decisions
Lead or support other internal business development partnering and strategic projects as directed that may be outside the scope of Hypercon
Qualification
Required
Minimum Bachelor's degree in a life sciences or related technical field with 18 years of relevant experience. Master's and/or PhD preferred (an equivalent combination of experience and education may be considered)
Minimum of 12 years experience in a pharmaceutical/biotech company or healthcare focused consulting role
Previous business development experience, including experience with evaluation activities such as market assessments, financial modeling, business case development and contract generation
Proven success in identifying new business opportunities and supporting execution of licensing agreements from start through close
Strong business, negotiation, organizational project management, analytical decision-making, and influence management skills are required
Knowledge of pharmaceutical and biotech clinical development and regulatory processes
Ability to effectively communicate and influence a broad variety of business leaders, both internally and externally and of varying levels from functional subject matter experts to senior leaders of companies is required
Deep network of connections across major pharmaceutical and biotech companies
Deal sheet summarizing accomplishments
Knowledge of industry databases and data room software
Preferred
Corporate account management and direct selling experience strongly preferred
Benefits
Full and comprehensive benefit program, including an Employee Stock Purchase Program and 401(k) matching.
Opportunities to grow in a culture that prioritizes learning, development and progression through in-house programs and tuition reimbursement.
Company
Elektrofi
Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.
51-200 employees
Funding
Current Stage
Growth StageTotal Funding
$154.11MKey Investors
National Science Foundation
2025-10-01Acquired
2024-08-22Series C· $112.25M
2022-06-13Series B· $40M
Leadership Team
Victoria Sluzky
Chief Technology Officer
Recent News
The Motley Fool
2026-01-24
GlobeNewswire
2026-01-12
The Motley Fool
2025-12-06
Company data provided by crunchbase